ライフサイエンスコーパス: implant

1 a high His-Bundle pacing threshold (n=23) at implant.

2 t favored the 10-mug implant over the 15-mug implant.

3 the effusion fluid surrounding the affected implant.

4 implant than the BGI's 350 mm(2) plate size implant.

5 ity and 1 system infection at 54 months post-implant.

6 ety-four eyes of 66 patients received an FAc implant.

7 n off the left ventricular (LV) lead at LVAD implant.

8 BIA-ALCL were estimated per patient and per implant.

9 er sizes than in functioning nonencapsulated implants.

10 of fenestration and dehiscence around dental implants.

11 sed for sensing and actuation for biological implants.

12 increase in pullout strength compared to SS implants.

13 est groups around both titanium and zirconia implants.

14 pplied to in situ forming implants and solid implants.

15 signs of histopathology compared to placebo implants.

16 ls within two weeks after the removal of the implants.

17 educe microbial numbers in a host if used as implants.

18 peri-implant mucositis and peri-implantitis implants.

19 nes compared to the adenovirus-Empty-treated implants.

20 y giant cells, to respond to the biomaterial implants.

21 Nine patients had a second valve implanted.

22 textured implants and 1.15 per 1000 textured implants (1 in 871), with a median time to diagnosis of

23 6.1%), bleb revision (23.9%), and tube shunt implant (13.2%).

24 A total of 111 eligible patients (n(implants) = 501) were assessed.

25 tients occurred most commonly <5 years after implant (54%) and decreased in frequency with increasing

26 This surgical procedure to implant a tube into the posterior chamber of the pseudop

27 In this study, we implanted a window to the mouse uterus to visualize the

28 al course, treatment, and outcomes in breast implant ALCL patients.

29 2 women with pathologically confirmed breast implant ALCL.

30 chemic times, whereas offering protection of implanted allografts during early stages of reperfusion

31 Although chronic implants allow for high-quality, long-term recordings in

32 Patients were 38+/-17 years at implant and 45 (21%) experienced appropriate interventio

33 % (79/196) of eyes assigned and treated with implant and 8% (17/209) of eyes assigned and treated wit

34 t disease, with an excellent prognosis after implant and capsule removal.

35 Generation 2 or 3 S-ICD devices were implanted and programmed with rate-based therapy deliver

36 9 per 1000 patients (1 in 559) with textured implants and 1.15 per 1000 textured implants (1 in 871),

37 and peri-implantitis occurred in 8.7% of the implants and 15.2% of the subjects.

38 -implant mucositis was found in 35.3% of the implants and 52.2% of the subjects, and peri-implantitis

39 rch, since microbial colonization of medical implants and devices is a ubiquitous problem in the fiel

40 actone have been used to formulate subdermal implants and injectable microspheres to eliminate the ne

41 here can also be applied to in situ forming implants and solid implants.

42 ase, repairs bone defects surrounding dental implants, and reverses alveolar bone loss following extr

43 s implanted in the "exemplar" unit with THRs implanted anywhere else in the registry.

44 The XEN45 was implanted as a stand-alone procedure or at the time of c

45 Adjusted analyses restricted to the same implants as the exemplar unit show no demonstrable diffe

46 The oncogenic events involved in breast implant-associated anaplastic large cell lymphoma (BI-AL

47 Breast implant-associated anaplastic large-cell lymphoma (BIA-A

48 Glaucoma drainage implant-associated endophthalmitis was correlated with p

49 study included patients that received dental implants at the University of Florida from 2011 to 2016.

50 as led to magnetically powered bioelectronic implants based on induction or magnetothermal effects.

51 large multisite cohort of patients (n = 66) implanted bilaterally in globus pallidus internus (n = 3

52 nse to H(2) at levels relevant to in vivo Mg-implant biodegradation compared to the other indicator/A

53 Implanted bioengineered livers have not exceeded three d

54 on wound healing and macrophage response to implanted biomaterials are discussed with the vision of

55 overcomes the time limitation of permanently implanted biosensors and that the biosensors detect rele

56 positive and displayed minor changes in peri-implant bone, characteristic of subclinical infection.

57 muCT measurements of the ex vivo peri-implant bony structure after 12 weeks follow-up covered

58 Peri-implant BOP was significantly higher among CS and NS wit

59 The implant Breast Reconstruction evAluation prospective coh

60 acture is a common adverse outcome following implant breast reconstruction, often associated with rad

61 Implants buccally positioned in the CBCT's were 34 times

62 ting of a long-acting reservoir subcutaneous implant capable of releasing cabotegravir for several mo

63 MitraClip extend to patients with previously implanted cardiac resynchronization therapy (CRT) is unk

64 A recent study in unilaterally implanted CI users showed that sound-localisation was im

65 Cochlear-implant (CI) users rely on temporal envelope modulations

66 to a chronic inflammation in and around the implanted collagen membranes, which reduces membrane lon

67 d proximal hygiene is associated to the peri-implant condition.

68 ding BTMs, a more refined definition of peri-implant conditions according to biological characteristi

69 mensionally (3D) printed bioceramic (BioCer) implants consisting of additively manufactured titanium

70 e tissue-implant interface in response to Ti implants, contributing to a twofold increase in pullout

71 -3p, miRNA-150-5p, and miRNA-26a-5p) in peri-implant crevicular fluid (PICF) of subjects with healthy

72 Clinical measurements and peri-implant crevicular fluid (PICF) were taken at 1-, 2-, 4-

73 nd OPG concentrations were estimated in peri-implant crevicular fluid using enzyme-linked immunosorbe

74 ally record local field potentials (LFPs) at implanted DBS leads was validated in patients with neuro

75 efficient power delivery to mm-scale devices implanted deep within soft tissues of the body.

76 20/550, and the patient with the off-center implant demonstrated 20/800 acuity.

77 The 3 with optimal placement of the implant demonstrated prosthetic acuity of 20/460 to 20/5

78 ctive analysis of cEEG data recorded with an implanted device in adults (age >=18 years) with drug-re

79 The implanted devices included 38 dual-chamber pacemakers, 1

80 ulate the performance and response of deeply implanted devices to US stimulation and composed by a do

81 Peri-implant disease (PID) has not been directly linked to pa

82 In turn, the diagnosis of peri-implant disease was significantly associated to the quan

83 w definition on the future reporting of peri-implant disease.

84 7 the World Workshop on Periodontal and Peri-implant Diseases and Conditions established new criteria

85 Peri-implant diseases are prevalent in this North African pat

86 onsidered to be the underlying cause of peri-implant diseases.

87 ariables to determine the prevalence of peri-implant diseases.

88 nt-level variables were associated with peri-implant diseases.

89 Overall, 28.74% implants displayed SUP within patients with peri-implant

90 The average legal indemnity for incorrect implant during cataract surgery was $57 514 (United Stat

91 -tech innovation that so far has mostly been implanted during cataract surgery, is a microelectronic

92 A total of 531 durable MCSs after ECLS were implanted during this period.

93 information-limiting correlations exist, we implanted eight Utah arrays in prefrontal cortex (PFC; a

94 were not dependent on the trajectory of the implanted electrode nor on first surgery pneumocephalus

95 immunohistochemistry showed that chronically implanted electroencephalography electrodes were surroun

96 e biosensor cannot be easily replaced (e.g., implanted electronics).

97 No implant failed throughout the study period and marginal

98 inosa), the most common cause of biomaterial implant failure in modern medicine.

99 rs of antidepressants were at higher risk of implant failure than non-users.

100 different antidepressant classes with dental implant failure.

101 ri-implant inflammation, history of previous implant failures, and pain/discomfort at the implant sit

102 of transmucosal prosthetic components or the implant fixture surface.

103 nts aged >=18 years scheduled to receive DEX implant for DME-related visual impairment.

104 dulation (SNM) in a large cohort of patients implanted for at least 10 years, quantify adverse event

105 Data collected prospectively from patients implanted for fecal incontinence (FI) in 7 French center

106 have provided the tools required to develop implants for applications so far technically impossible.

107 New depot and implant formulations of buprenorphine and naltrexone hav

108 eased in frequency with increasing time from implant (from 9.7% of patients at <5 years to 3.8% at >=

109 The implant has substantially higher risk of glaucoma than s

110 Variation in the survival of THR implants has been observed between units and reducing th

111 The implants have a 47 mm lumen length, 3.6 mm outer diamete

112 cessful outcome was described as either peri-implant health after complete regeneration or peri-impla

113 onfirmed reliable discriminants between peri-implant health and disease, while increase in PD (PD > 4

114 ctive treatment of peri-implantitis: 1) peri-implant health with a reduced support, 2) peri-implant m

115 essful treatment outcome was defined as peri-implant health with a reduced support, whereas, after re

116 t health after complete regeneration or peri-implant health with a reduced support.

117 In vivo, tumour growth of implanted human TNBC cells and the number of circulating

118 ponse patterns to intravitreal dexamethasone implants (IDI) in naive and previously treated (PT) diab

119 CRT was programmed off after LVAD implant in 44 patients.

120 The EYEMATE-IO implant was successfully implanted in 22 patients with few surgical complications

121 l (BFC) and an animal brain stimulator (ABS) implanted in a pigeon.

122 studies using B16-F10 melanoma cancer cells implanted in C57/BL6 mice demonstrate improved rates of

123 th control patients who received new devices implanted in Canada.

124 ets from rats encapsulated in the device and implanted in diabetic mice restored normoglycaemia in th

125 We applied this procedure to electrodes implanted in human epilepsy patients (both male and fema

126 ned direct neural recordings from electrodes implanted in human subjects and showed that activations

127 ntubular engineered organs have already been implanted in patients, in vitro formation of a fully fun

128 es of appropriate therapies, including those implanted in primary prevention.

129 We compared survival of THRs implanted in the "exemplar" unit with THRs implanted any

130 m control implants with similar designs were implanted in the ovine skull and at s.c. sites and retri

131 stiff, causing damage to the tissue they are implanted in.

132 ect of the inhibitors on release of Dox from implants in PBS, in vivo Dox distribution and retention

133 of >=2 mm was found in 59% and 47.2% of the implants in the ChxC and control groups, respectively (P

134 hs are obtained for the lens and disk-shaped implants in the higher spectrum.

135 There were 22 second-time GDD implants in the study, of which 11 failed (50%), and inc

136 human bone platform for advanced testing of implants in vitro, and demonstrate the scientific validi

137 tracellular matrix in human TMJ-OA cartilage implants in vivo.

138 edic surgeons are concerned with the risk of implant infections following a dental procedure and, the

139 Inadequate plaque control, peri-implant inflammation, history of previous implant failur

140 ubsequent initiation and progression of peri-implant inflammatory diseases.

141 All of the 41 patients with known implant information had implants with textured surface.

142 aluate the prevalence of peri-implantitis in implants inserted in augmented maxillary sinuses and to

143 les; mean age: 60.9 +/- 11.6 years) with 315 implants inserted into augmented maxillary sinuses with

144 ization and calcium deposition at the tissue-implant interface in response to Ti implants, contributi

145 odegradable scaffolds, along with MDSCs, are implanted into corpus cavernosa defects in a rabbit mode

146 Human pancreatic tumor tissues were implanted into interscapular fat pads of NSG mice, and m

147 hat were coated with T-cell-loaded films and implanted into subcutaneous tumours in mice improved the

148 ar endothelial growth factor (VEGF) could be implanted into the arterial system of a pre-clinical ovi

149 to a bundle of drivable microwires was later implanted into the rNTS.

150 ilicon based laminar neural electrode arrays implanted into V1m cortex of mice.

151 ne of immediately placed and provisionalized implants is accompanied with more loss of BBT, but at th

152 Exclusion criteria were newly implanted leads, abandoned or epicardial leads, and depe

153 drop in peri-implantitis at both patient and implant level of nearly 50% from the prior analysis.

154 The survival rate at the implant level was 90% in the test group and 81.6% in the

155 he subject level, and 68.4% and 22.7% at the implant level, respectively.

156 ession analyses have been performed for both implant-level and patient-level variables.

157 Multiple subject- and implant-level variables were associated with peri-implan

158 We tested the hypothesis that implant loosening is associated with changes in the gut

159 olation and had an implantable loop recorder implanted <3 months post-ablation.

160 yield decrease after one week, while the L1 implants maintained a high SU yield throughout the 16 we

161 lly significant increase in adherence to the implant maintenance routine was observed after IR.

162 Peri-implant marginal mucosa defects (PMMDs) are alterations

163 e resorption and bone quality parameters, no implant material was superior to the other.

164 ficial surgical site infection following SCS implant may be treated with antibiotic therapy alone, de

165 Peri-implant MBLs were frequently located in a zone within 1

166 l biofilms, especially those associated with implanted medical devices, are difficult to eradicate.

167 s concluded that an optimal range of initial implant micromotion could be designed for a specific pat

168 ng-term (bone remodeling) effects of initial implant micromotion during the healing phase were studie

169 In cases with small implant micromotion, tissue between the implant threads

170 in, and peroxidasin gene expressions in peri-implant mucosa were noted within both groups (P < 0.05)

171 grafting has a beneficial effect on the peri-implant mucosa, but the effect of grafting the buccal mu

172 fluid (PICF) of subjects with healthy, peri-implant mucositis and peri-implantitis implants.

173 mixed models RESULTS: The prevalence of peri-implant mucositis and peri-implantitis were 82.1% and 41

174 ith peri-implantitis in comparison with peri-implant mucositis sites (P = 0.011, P = 0.020, respectiv

175 Using the 2017 criteria, peri-implant mucositis was found in 35.3% of the implants and

176 plant health with a reduced support, 2) peri-implant mucositis with a reduced support, and 3) recurre

177 54 patients were enrolled into healthy, peri-implant mucositis, and peri-implantitis groups.

178 achment and bidirectional communication with implanted neuromuscular electrodes.

179 on ECMO or with nondischargeable, surgically implanted, nonendovascular support devices (TCS-VAD) to

180 Detection of amyloid in intraportal islet implants of type 1 diabetes patients has been proposed a

181 atients underwent reconstruction with 16,065 implants, of which 9589 (59.7%) were textured.

182 ystemic therapy (censoring eyes receiving an implant on implantation) developed glaucoma (hazard rati

183 TG) in the esthetic zone of single immediate implants on the change of BBT according to cone beam com

184 h a tube shunt (350-mm(2) Baerveldt glaucoma implant) or trabeculectomy with mitomycin C (MMC; 0.4 mg

185 e risk-benefit assessment favored the 10-mug implant over the 15-mug implant.

186 year to 8.5% of patients at >=10-years after implant (P=0.005).

187 t increase in frequency over follow-up after implant (P=0.47).

188 ts well-known role as a risk factor for peri-implant pathologies.

189 Of 20 implanted patients, 17 completed 3-year follow-up (maxim

190 95 patients with 220 implants who had their implants placed between 1998 and 2003.

191 Implants placed in the lower anterior jaw region had the

192 MT was assessed prior to implant placement and 1, 6, and 12 months after treatmen

193 upper molar was performed at 1 year, dental implant placement at 2 years, and sacrifice at 28 months

194 Smoking at time of implant placement emerged as a new risk factor in this a

195 mpare soft tissue healing outcomes following implant placement in grafted (GG) and non-grafted bone (

196 certain patient reluctance to undergo future implant placement in the same clinic or with the same pr

197 truction in irradiated patients, subpectoral implant placement was nearly 4 times as likely to result

198 ne patients requiring extraction and delayed implant placement were placed into three groups: extract

199 mensional (3D) ridge changes after immediate implant placement with and without immediate provisional

200 using FGG at second stage surgery following implant placement.

201 study measurements, a bone core sample, and implant placement.

202 hed Ti discs were inoculated with human peri-implant plaque biofilms and mechanical antimicrobial int

203 soft tissue grafts for periodontal and peri-implant plastic surgical reconstruction.

204 Peri-implantitis patients with implant pocket depths (IPD) of 5-8 mm underwent subgingi

205 portant in dental implantology, in which the implant position and dimensions are currently determined

206 The bucco-palatal implant position was the most relevant factor related to

207 bedded in a soft, circumneural sciatic nerve implant, powered and driven by a miniaturized head-mount

208 It was found that a lens-shaped implant produces higher peak echoes in the breast for fr

209 The BioCer implant promoted bone regeneration at nonosseous sites,

210 Results from implanting prostate graft tissues derived from the compo

211 Here, we show that BioCer implants provide osteoinductive and microarchitectural c

212 quelae and patient satisfaction after dental implant removal (IR).

213 table microspheres to eliminate the need for implant removal and reduce provider intervention.

214 18.6 and 8.86 times more likely to lose the implant, respectively, when compared with <25% MBL.

215 The success of debridement, antibiotics, and implant retention (DAIR) in early periprosthetic joint i

216 ed with debridement, antibiotic therapy, and implant retention (DAIR).

217 These implanted scaffolds promote tissue ingrowth, which upon

218 ants selected their preferred IOL, which was implanted sequentially into each eye of patients meeting

219 gnificance was found on the distance between implant shoulder and the buccal bone plate (BID) effect.

220 Adenovirus LOXL2 -treated implants showed higher mRNA levels of LOXL2, ACAN, and o

221 implant failures, and pain/discomfort at the implant site were significantly associated with both out

222 entation using free gingival grafts (FGG) at implant sites over a 3-month follow-up period.

223 gineer three-dimensional channel networks in implant sites, without any therapeutic treatment.

224 defects (PMMDs) are alterations of the peri-implant soft tissue architecture characterized by an api

225 However, the influence on peri-implant soft tissue healing is unclear.

226 The tissue/implant specimens were then individually placed at an ai

227 ropose a framework for the diagnosis of peri-implant status after surgical treatment for peri-implant

228 Periodontal and peri-implant status were assessed based on clinical and radio

229 ivity stemming from artificial (i.e., neural implant) stimulation and on the relative timing between

230 erent samples in TMJ-OA cartilage plugs were implanted subcutaneously in nude mice.

231 n to be efficiently biodegraded in vivo when implanted subcutaneously in rats.

232 therapy (PhMT-s) at sites with a tooth or an implant supported fixed dental prosthesis.

233 After delivery of the final implant-supported restoration, follow-up visits were sch

234 depths (IPD) of 5-8 mm underwent subgingival implant surface debridement followed by repeated bi-week

235 stigate the effect of a potential biological implant surface disinfectant, leukocyte- and platelet-ri

236 the proper attachment of epithelium to tooth/implant surface.

237 his has inspired the design of antibacterial implant surfaces with insect-wing mimetic nanopillars ma

238 The average implant survival time before IR was 120.3 +/- 88.2 month

239 planted with an osseointegrated percutaneous implant system for direct skeletal attachment and bidire

240 to overcome shortcomings in CIs by improving implant technology and surgical techniques, but with lim

241 Using an implanted telemeter to record cardiovascular parameters,

242 The MGI required less time to implant than the BGI's 350 mm(2) plate size implant.

243 when functional, and in all intraperitoneal implants that corrected diabetes in mice, exhibiting lar

244 ntic posts (n = 23) were used to function as implants that were inserted into the center of full-thic

245 Implants that were placed in sites with a previous apica

246 Predictors of reduced incidence of IAS were implanting the most recent generation of device, using t

247 ality of information provided at the time of implant therapy (P = 0.004), including the influence of

248 Following application of PSMNs to the skin, implanted thin films facilitated sustained and temporal

249 mall implant micromotion, tissue between the implant threads differentiated into bone during the heal

250 scheduled at 6 and 12 months to monitor peri-implant tissue health and marginal bone levels using sta

251 acterial decontamination and modulating peri-implant tissue inflammation.

252 adiographically to assess the status of peri-implant tissues and teeth.

253 After the first year of treatment peri-implant tissues showed continuous changes resulting in a

254 was not perfused with EVNP and was directly implanted to a 64-year-old patient.

255 nal and fetal catheters and flow probes were implanted to determine cardiovascular and metabolic chan

256 ect fillers (cements) and allow personalized implants to be rapidly prototyped by 3D bioprinting.

257 ture diagnostic assays for women with breast implants to distinguish seroma caused by BIA-ALCL from o

258 verslip implantation, large craniotomies for implanting transparent polymer skulls for cortex-wide im

259 corrected visual acuity (BCVA) was stable; 3 implant-treated subjects with corneal TEAEs had >2-line

260 -term bone healing/adaptation after a dental implant treatment starts with diffusion of mesenchymal s

261 ixation via bony growth into a porous-coated implant (uncemented) or with cement.

262 Collagen membrane discs were implanted under the scalp in diabetic (streptozotocin-in

263 s flow Left Ventricular Assist Device (LVAD) implant vary: some centers continue CRT while others tur

264 while the latter require invasive surgery to implant vascularized scaffolds.

265 otic therapy alone, deep infection involving implant warrants device removal to achieve cure.

266 The mean LBBP capture threshold at implant was 0.62+/-0.21 V at 0.4 ms which remained stabl

267 at nonosseous sites, and bone bonding to the implant was demonstrated at the ultrastructural level.

268 The EYEMATE-IO implant was successfully implanted in 22 patients with f

269 hereas bone regeneration with inert titanium implants was confined to ingrowth from the defect bounda

270 Both dose strengths of bimatoprost implant were noninferior to timolol in IOP lowering afte

271 ann applanation tonometry and the EYEMATE-IO implant were performed.

272 ar) and subsequent replacement with a dental implant were recruited and randomly allocated into one o

273 oth to be extracted and replaced by a dental implant were recruited for this study.

274 A total of 771 patients and 1,820 implants were evaluated.

275 patients treated with single-tooth maxillary implants were included in this study.

276 e of random extent ("depth") was created and implants were mounted with different abutment/crown mate

277 Implants were placed for augmentation in 61.5% of women

278 Following 2 to 8 months of healing, all implants were uncovered and connected to the correspondi

279 he acoustic signals generated by disk-shaped implants when stimulated by external US sources in the h

280 proaches include optogenetics and prosthetic implants, which aim to bypass lost photoreceptors (PRs).

281 er the physiological consequences of cranial implants, which include glial scarring, meningeal lympha

282 study was performed on 95 patients with 220 implants who had their implants placed between 1998 and

283 (i.e., <2 mm) at the vestibular aspect of 19 implants who underwent soft tissue augmentation using FG

284 s in which a device was deployed, 98.1% were implanted with <5-mm leak.

285 hundred twenty-seven eyes (84 patients) were implanted with 215 ICRSs during the study period, and 77

286 maller pupil size (P = .05) than normal eyes implanted with aberration-free IOLs.

287 Three transhumeral amputees were implanted with an osseointegrated percutaneous implant s

288 Newer models are derived in cohorts implanted with continuous-flow LVADs exclusively and exh

289 tions that recordings from neurons in humans implanted with electrodes for clinical purposes have mad

290 All consecutive patients implanted with Intacs ICRS at a single center by 1 of th

291 Longer-term follow-up of patients implanted with INTACS is important to monitor if this co

292 s prediction in human neurosurgical patients implanted with intracranial electrodes.

293 Rats were implanted with recording arrays in the BLA and, after re

294 Patients who passed screening criteria were implanted with the DBS device bilaterally in the subthal

295 LAAO Registry has enrolled >38,000 patients implanted with the device.

296 Twenty-two patients previously implanted with the EyeMate were requested to obtain at l

297 nveloped with CaP BioCer or titanium control implants with similar designs were implanted in the ovin

298 patients with known implant information had implants with textured surface.

299 ular Micro-Bypass Stents and 2 iStent Inject implants with the Hydrus Microstent.

300 The non-human primates tolerated the implant without gross pathology or microscopic signs of

301 vast majority of CI users who have only one implant, without the expense and risk of a second implan